Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Carcinoma, Squamous Cell 1Carcinoma 1Breast Neoplasms 1Anatomic Stage III Breast Cancer AJCC v8 1

Interventions

Cisplatin 3X-Rays 2zimberelimab 1durvalumab 1dl1520 1cemiplimab 1balstilimab 1Taxes 1Standard of Care 1Radiation 1Practice Guidelines as Topic 1Polymerase Chain Reaction 1Narrow Band Imaging 1Magnetic Resonance Spectroscopy 1MEDI0457 1Lansoprazole 1Gene Expression Profiling 1Gabapentin 1Fluorouracil 1Fluorodeoxyglucose F18 1Exercise Test 1Drug Delivery Systems 1Dexlansoprazole 1Cetuximab 1Blood Specimen Collection 1Alpelisib 1Absorptiometry, Photon 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Oropharyngeal Neoplasms × Alpelisib × Clear all
NCT02298595 2017-11-13

Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

University of Pittsburgh

Phase 1/2 Withdrawn
Head & Neck

Carcinoma, Carcinoma, Squamous Cell, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡